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Abstract
Background: The ideal medication for acid-related diseases should have a rapid onset of action to promote
hemostasis and cause efficient resolution of symptoms. The aim of our study was to comparatively investigate the
inhibitory effect on gastric acid secretion of a single oral administration of omeprazole plus mosapride with that of
omeprazole alone.
Methods: Ten Helicobacter pylori-negative male subjects participated in this randomized, two-way crossover study.
Intragastric pH was monitored continuously for 6 hours after a single oral administration of omeprazole 20 mg or
that of omeprazole 20 mg plus mosapride 5 mg (the omeprazole being administered one hour after the
mosapride). Each administration was separated by a 7-days washout period.
Results: The average pH during the 6-hour period after administration of omeprazole 20 mg plus mosapride 5 mg
was higher than that after administration of omeprazole 20 mg alone (median: 3.22 versus 4.21, respectively; p =
0.0247).
Conclusions: In H. pylori -negative healthy male subjects, an oral dose of omeprazole 20 mg plus mosapride 5 mg
increased the intragastric pH more rapidly than omeprazole 20 mg alone.
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Background
The ideal medication for gastric acid-related diseases,
especially for conditions like hemorrhagic gastric ulcers
and stress-related gastric bleeding, should have a rapid
onset of action to lower the intragastric acidity, because
in vitro studies have shown that blood coagulation and
platelet aggregation are abolished at pH less than
5.4 [1]. Medication for on-demand treatment should
also have a rapid onset of action to ensure that the
symptoms are controlled. Multiple agents, including
antacids, histamine H2 receptor antagonists (H2RA) and
proton pump inhibitors (PPI), are currently available for
the treatment of these diseases. PPIs are the most potent
inhibitors of gastric acid secretion when used regularly
[2]. Our previous study demonstrated that administration
of H2RA plus mosapride (orally) increased the intragas-
tric pH more rapidly than that of H2RA alone [3]. How-
ever, no study has yet examined whether administration
of PPI plus mosapride (orally) may also produce a more
rapid increase of the intragastric pH than that of a PPI
alone. This crossover study was designed to compare the
acute effect on the intragastric pH of administration of
omeprazole 20 mg alone with that of omeprazole 20 mg
plus mosapride 5 mg.
Methods
Subjects
This was a randomized, two-way crossover study con-
ducted on 10 healthy male volunteers, mean age 29.4
years (range 23 - 35 years), who were not users of acid
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suppressive medications, including antacids, H2RAs, and/
or PPIs. All subjects were negative for anti- Helicobacter
pylori (H. pylori) immunoglobulin G antibodies using E
plate EIKEN H. pylori antibody (Eikenkagaku Inc,
Tochigi, Japan).
Study protocol and pH-metry
All subjects followed two study protocols in which they
were given 20 mg omeprazole (Omeprale, Astrazeneka
Pharmaceutical Co. Ltd, Tokyo, Japan) orally, or 20 mg
omeprazole plus 5 mg mosapride (Gasmotin, Dainippon
Sumitomo pharmaceutical Co. Ltd, Osaka, Japan), with
the omeprazole being administered one hour after the
mosapride. Intragastric pH was monitored continuously
for 6 hours after each protocol. There was a washout per-
iod of at least 7 days between each protocol. The subjects
fasted overnight (at least 8 hours) before each treatment
protocol and during the 6 hours after ingestion of the
drug or drugs, and both experiments were performed in
the morning.
The pH electrode was inserted transnasally under local
anesthesia and located in the body of the stomach. The
gastric pH was measured at 10-second intervals by a por-
table pH meter fitted with an antimony pH electrode
(Chemical Instrument Co. Ltd, Tokyo, Japan). The pH
electrode was calibrated before each recording using stan-
dard buffers of pH 4.01 and 6.86. The pH data were ana-
lyzed using established software (Chemical Instrument Co.
Ltd, Tokyo, Japan). The average pH and the percent dura-
tions over which the intragastric pH remained above 1, 2,
3, 3.5, 4, 5, 6, 7 and 8 during the 6-hour monitoring period
after the administration of each drug were also measured.
Statistics
Statistical evaluation was carried out using the Wilcoxon’s
signed-rank test. The level of significance was set at p <
0.05. All the statistical analyses were performed using the
StatView program (SAS Institute, Cary, NC, USA).
Ethics
The study was conducted in accordance with the princi-
ples of the Declaration of Helsinki, and with the approval
of the Ethics Committee of Yokohama City University
School of Medicine. We obtained informed consent for
participation in the study from all the volunteers.
Results
All subjects completed the study. No adverse events
were recorded during the study.
Average pH
The average pH during the 6-hour period after the admin-
istration of omeprazole 20 mg plus mosapride 5 mg was
higher than that after administration of omeprazole 20 mg
alone (median: 4.21 versus 3.22, respectively; p = 0.0247)
(Figure 1).
The average pH was significantly higher after adminis-
tration of omeprazole 20 mg plus mosapride 5 mg than
that after omeprazole 20 mg alone during the 3 to 4
and 4 to 5-hour study periods (median: 4.35 versus 2.75;
p = 0.0284, 5.35 versus 3.45; p = 0.0093) (Figure 2). No
significant differences were found in the 0-1, 1-2, 2-3
and 5-6 hour study periods.
Holding time (%) of various pH levels over the 6-hour
monitoring period
During the 6-hour study period, administration of ome-
prazole 20 mg plus mosapride 5 mg provided a longer
duration of pH > 3, 3.5, 4, 5, 6 and 7 as compared with
that of omeprazole 20 mg alone (median: 67.6% versus
36.8%; p = 0.0367, 55.9% versus 34.1%; p = 0.0469,
49.5% versus 28.7%; p = 0.0367, 45.6% versus 16.8%; p =
0.0217, 38.6% versus 7.6%; p = 0.0109, and 20.4% versus
4.4%; p = 0.0173) (Figure 3). duration of pH > 2 com-
pared to omeprazole 20 mg alone (median: 80.2% versus
62.6%; p = 0.5076)
Discussion
In this study, we examined the change of the intragastric
pH after a single oral administration of omeprazole
20 mg plus mosapride 5 mg as compared with that fol-
lowing administration of omeprazole 20 mg alone in the
early post-administration phase in H. pylori-negative
subjects.
Mosapride citrate (mosapride) (4-amino-5-chloro-2-
ethoxy-N-{[4-(4-fluorobenzyl)-2-morpholinyl]methyl}
benzamide citrate) is a novel gastrokinetic agent that
enhances gastrointestinal motility by stimulating the ser-
otonin (5-HT4) receptor [4]. Mosapride stimulates acet-
ylcholine release from the cholinergic nerve endings in
Figure 1 Average pH during the first 4 hours was higher after
administration of omeprazple with mosapride than after
omeprazole. *(p = 0.0247 by the Wilcoxon signed-ranks test).
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the gastrointestinal wall and may enhance upper gastro-
intestinal motor activity in the postprandial state in con-
scious dogs [5]. After oral administration, mosapride is
absorbed in the small intestine in rats, rather than in
the stomach [6].
Mosapride accelerates gastric emptying in healthy
adults. This study may indicate that mosapride acceler-
ates the absorption of omeprazole. For example, mosa-
pride accelerated the gastric emptying and completion
rate of small bowel examinations in patients undergoing
capsule endoscopy [7]. The gastric emptying time (GET)
in the mosapride group was reduced and indicated the
obvious effect of mosapride on the shortening of the
GET. Moreover, preparation for barium enemas using
mosapride before and after oral intestinal lavage solution
(PEG-ELS) intake is more effective than the modified
Brown’s method that is commonly used in Japan [8].
Mosapride improves gastrointestinal motility and
reduces gastric stasis or gastroesophageal reflux [9,10].
Mosapride also alleviates gastrointestinal dysfunction.
Although many factors are implicated in the develop-
ment of gastroesophageal reflux disease (GERD), acid
reflux to the esophagus is considered to be the major
cause of this disease. Treatment with PPIs to provide
potent, long-term suppression of gastric acid is essential
for disease management. On the other hand, the transient
heartburn associated with mild GERD is attributed mainly
to temporary, short-term gastric acid reflux. For example,
water and antacid immediately increased the gastric pH,
while PPIs showed a delayed, but prolonged effect as com-
pared to H2RAs [11]. Therefore, rapid acid suppression is
one of the most important factors for the resolution of
these symptoms. Because administration of omeprazole
plus mosapride promptly suppressed gastric acid secretion
[12], it was originally considered to be a useful drug for
on-demand treatment of mild GERD. Omeprazole used
with mosapride may accelerate the onset of action, and
may thus be more suitable for on-demand use than ome-
prazole alone. Furthermore, fixed mosapride-omeprazole
combination therapy may be more useful than omeprazole
alone.
If mosapride accelerates the absorption of omeprazole,
why was the gastric pH not higher during 0-1, 1-2, or 2-3-
hour period (Figure 2)? We suspect that mosapride has
not so quick and strong effect for earlier phase of gastric
emptying. If mosapride can accelerate gastric emptying
quickly for 1 hour compare to control, earlier effect may
be observed during 0-1 or 1-2 or 2-3 hour study period.
Intragastric pH during 3-4-hour study period was
fallen (Figure 2). Why this transient decrease of intra-
gastric pH observed using PPI? Because PPI can block
only activated proton pomp, gastric pH does not reflect
blood concentration of omeprazole directory. Our pre-
vious manuscripts [13-15] reported that after PPI
administration, intragastric pH value raise showing up
and down.
The limitations of the present study are: short time (6
hours) study period may be insufficient for the end of
both mosapride’s and omeprazole’s effects for intragas-
tric pH, and data were collected from healthy volunteers
and not GERD patients requiring on-demand therapy.
Further study may be necessary to evaluate these
problems.
The ideal medication for the treatment of heartburn
should have the rapid onset of action needed for on-
demand treatment, as well as a sufficient duration of
Figure 2 Omeprazole 20 mg with mosapride 5 mg provided a
higher average pH, compared to omeprazole 20 mg alone, at
the 3-4 hour and 4-5 hour study period after administration.
Squares (omeprazole with mosapride) and circles (omeprazole), mean
values; vertical lines, standard deviation (SD); horizontal line, ± SD.
*p = 0.0284 and 0.0093 by the Wilcoxon signed-ranks test.
Figure 3 During the 4-hour study period, omepraaole 20 mg
with mosapride 5 mg provided a longer duration of pH > 3,
3.5, 4, 5, 6 and 7, compared to omeprazole 20 mg alone.
Squares (omeprazole with mosapride) and circles (omeprazole),
mean values; vertical lines, standard deviation (SD); horizontal line, ±
SD. *p = 0.0367, 0.0469, 0.0367, 0.0217, 0.0109 and 0.0173 by the
Wilcoxon signed-ranks test.
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action to ensure that the symptoms are controlled. On the
basis of our results, we conclude that omeprazole 20 mg
plus mosapride 5 mg produced a rise in intragastric pH
more promptly than omeprazole 20 mg alone in H. pylori-
negative healthy male subjects. The clinical implications of
our results remain unclear; however, our findings suggest
that oral administration of the combination of omeprazole
20 mg preceded by mosapride 5 mg tablets may be suita-
ble for on-demand treatment in patients with mild GERD.
Further study may be necessary to evaluate the effects in
GERD subjects.
Conclusions
In conclusion, in H. pylori-negative healthy male sub-
jects, an oral dose of omeprazole 20 mg plus mosapride
5 mg increased the intragastric pH more rapidly than
that of omeprazole 20 mg alone.
Abbreviations
H2RAs: H2 receptor antagonists; PPIs: Proton pump inhibitors; 5-HT4: 5-
Hydroxytryptamine receptor 4; GET: Gastric emptying time; PEG-ELS:
Polyethylene glycol electrolyte; GERD: Gastroesophageal reflux disease.
Acknowledgements
The funding source had no involvement in the design, analysis, writing of
the paper, or decision to publish this work.
Special thanks to the medical staffs of the Gastroenterology Division,
Yokohama City University Hospital, Kanagawa, Japan.
Author details
1Gastroenterology Division, Yokohama City University School of Medicine,
3-9 Fukuura, Kanazawa-ku, Yokohama, Japan. 2Office of Postgraduate Medical
Education, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa-ku,
Yokohama, Japan. 3Department of Medical Education, Yokohama City
University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Japan.
Authors’ contributions
HI analyzed, collected the clinical data and wrote the manuscript, with
contributions from MI. AN was responsible for the design of the study and
collected the clinical data. MI performed the statistical analyses. HI and MI
analyzed the clinical data and participated in the design and coordination of
the study. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 25 October 2011 Accepted: 26 March 2012
Published: 26 March 2012
References
1. Green FW Jr, Kaplan MM, Curtis LE, Levine PH: Effect of acid and pepsin
on blood coagulation and platelet aggregation. A possible contributor
prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978,
74:38-43.
2. Burget DW, Chiverton SG, Hunt RH: Is there an optimal degree of acid
suppression for healing of duodenal ulcers? A model of the relationship
between ulcer healing and acid suppression. Gastroenterology 1990,
99:345-51.
3. Iida H, Inamori M, Nozaki Y, et al: Early effects of oral administration of
lafutidine with mosapride compared with lafutidine alone on
intragastric pH values. BMC Gastroenterology 2009, 9:52.
4. Yoshikawa T, Yoshida N, Mine Y, et al: Affinity of mosapride citrate, a new
gastroprokinetic agent, for 5-HT4 receptors in guinea pig ileum. Jpn J
Pharmacol 1998, 77:53-9.
5. Yoshida N, Ito T, Karasawa T, Itoh Z, et al: AS-4370, a new gastrokinetic
agent, enhances upper gastrointestinal motor activity in conscious dogs.
J Pharmacol Exp Ther 1991, 257:781-7.
6. Okuno T, Kobayashi H, Haruki S, et al: Pharmacokinetics of FRG-8813 in
Rats after Single Oral Dosing. Jpn J Pharmacol 1995, 23:87-104.
7. Wei W, Ge Z-Z, Hong Lu, et al: Effect of mosapride on gastrointestinal
transit time and diagnostic yield of capsule endoscopy. Gastroenterology
2007, 22:1605-1608.
8. Futei S, Sugino Y, Kuribayashi S, et al: New preparation method for barium
enema: efficacy and administration of oral intestinal lavage solution
with gastrointestinal prokinetic agent. Nippon Igaku Hoshasen 2004,
64:22-30.
9. Oshida N, Omoya H, Oka M, Furukawa K, Ito T, Karasawa T: AS-4370, a
novel gastrokinetic agent free of dopamine D2 receptor antagonist
properties. Arch Int Pharmacodyn 1989, 300:51-67.
10. Ruth M, Hamelin B, Rohss K, Lundell L: The effect of mosapride, a novel
prokinetic, on acid reflux variables in patients with gastro-oesophageal
reflux disease. Aliment Pharmacol Ther 1998, 12:35-40.
11. Karamanolis G, Theofanidou I, Yiasemidou M, Giannoulis E, Triantafyllou K,
Ladas SD: A glass of water immediately increases gastric pH in healthy
subjects. Dig Dis Sci 2008, 53:3128-32.
12. Inamori M, Togawa J, Iwasaki T, Ozawa Y, Kikuchi T, Muramatsu K,
Chiguchi G, Matsumoto S, Kawamura H, Abe Y, Kirikoshi H, Kobayashi N,
Shimamura T, Kubota K, Sakaguchi T, Saito S, Ueno N, Nakajima A: Early
effects of lafutidine or rabeprazole on intragastric acidity: which drug is
more suitable for on-demand use? J Gastroenterol 2005, 40:453-8.
13. Abe Y, Inamori M, Togawa J, et al: The comparative effects of single
intravenous doses of omeprazole and famotidine on intragastric pH. J
Gastroenterol 2004, 39:21-5.
14. Inamori M, Togawa J, Chiguchi G, et al: The Evaluation of Anti-secretory
Drugs on Intragastric Acidity; Are the Combined Therapy of a Proton
Pump Inhibitor and a H2 Receptor Antagonist Effective as an Initial
Treatment? J Gastroenterol 2005, 40:213-4.
15. Inamori M, Akimoto K, Akiyama T, et al: Is Oral Combination Therapy with
a Proton Pump Inhibitor and H2 Receptor Antagonist Effective as Initial
Treatment? J Gastroenterol 2007, 42:510-1.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-230X/12/25/prepub
doi:10.1186/1471-230X-12-25
Cite this article as: Iida et al.: Early effect of oral administration of
omeprazole with mosapride as compared with those of omeprazole
alone on the intragastric pH. BMC Gastroenterology 2012 12:25.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Iida et al. BMC Gastroenterology 2012, 12:25
http://www.biomedcentral.com/1471-230X/12/25
Page 4 of 4
